跳至主要内容
临床试验/NCT02238236
NCT02238236已完成不适用

Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Dry Syrup -Drug Use-Results Survey of Alesion® Dry Syrup-

Boehringer Ingelheim0 个研究点目标入组 3,793 人开始时间: 2005年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
3,793
主要终点
Incidence of adverse drug reactions

研究概览

简要总结

Study to investigate the safety and efficacy of Alesion® Dry Syrup under the proper use in daily clinical practice in Japanese paediatric patients with allergic rhinitis, eczema/dermatitis, urticaria and pruritus

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • All the patients who:
  • haven't treatment experience of epinastine product;
  • have at least one out of following diseases. allergic rhinitis, eczema, dermatitis, pruritus, urticaria

排除标准

  • Alesion® Dry Syrup is contraindicated for the patients with history of hypersensitivity to any ingredients of Alesion® Dry Syrup in package insert. However, it was unknown whether a patient was hypersensitive to the ingredients of the product in almost cases. And this survey was drug utilization study to observe actual use in any patients. Therefore exclusion criteria are not set in the protocol

研究组 & 干预措施

Patients with allergic rhinitis, eczema/dermatitis, urticaria

干预措施: Alesion® (Drug)

结局指标

主要结局

Incidence of adverse drug reactions

时间窗: up to 3 years

classified by Medical Dictionary for Regulatory Activities (MedDRA) terminology

Incidence of adverse drug reactions classified by patient's background/treatment factors

时间窗: up to 3 years

次要结局

  • Overall assessment of efficacy by investigator on a 3-point scale(At 12 weeks and 52 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验